Biotech Values

[ghmm]

I've looked at Morphosys a bit of late. Not as familiar with MEDX and SGEN but MorphoSys is basically an MAB company.

I took a pass (for now) since most of the programs are Phase 1 or earlier and for small royalties. They have a couple of their own programs and have an option to codevelop some targets with Novartis. If the valuation gets ridiculously cheap or as things advance I thought I'd take another look. I like that they have good revenues (from Novartis).